Chiasma Inc. (NASDAQ: CHMA) Attends 31st Annual ROTH Conference
Chiasma (NASDAQ: CHMA) is a biopharmaceutical company focused on improving the lives of patients who face challenges associated with existing treatments for their rare and debilitating diseases. Employing its Transient Permeability Enhancer (TPE) technology platform, Chiasma seeks to develop and ultimately commercialize oral medications that are currently only available as injections. The company is developing octreotide capsules (conditionally trade named Mycapssa) for the potential maintenance therapy of adult patients with acromegaly in whom prior treatment with somatostatin analogs has been shown to be effective and tolerated. For more information, visit the company's website at www.chiasma.com. About NetworkNewsWire NetworkNewsWire (NNW) is…







